Sirona Biochem Corp. (SRBCF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -28.76 Thousand CAD | -95.97% |
| 2022 | 621.75 Thousand CAD | 212.05% |
| 2021 | 199.25 Thousand CAD | 286.35% |
| 2020 | 51.57 Thousand CAD | -62.01% |
| 2019 | 135.74 Thousand CAD | -89.38% |
| 2018 | 1.27 Million CAD | 23285.06% |
| 2017 | 5468.00 CAD | -98.24% |
| 2016 | 309.88 Thousand CAD | 251.22% |
| 2015 | -204.91 Thousand CAD | -236.14% |
| 2014 | 150.51 Thousand CAD | 417.44% |
| 2013 | -47.41 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 8619.00 CAD | 1138.43% |
| 2024 Q1 | -830.00 CAD | 97.57% |
| 2024 Q3 | 2543.00 CAD | -70.5% |
| 2023 Q2 | 57.11 Thousand CAD | 2484.93% |
| 2023 FY | 25.07 Thousand CAD | -95.97% |
| 2023 Q1 | -2395.00 CAD | -131.4% |
| 2023 Q4 | -34.09 Thousand CAD | -868.03% |
| 2023 Q3 | 4439.00 CAD | -92.23% |
| 2022 Q4 | 7628.00 CAD | -98.83% |
| 2022 Q3 | 653.86 Thousand CAD | 246.59% |
| 2022 FY | 621.75 Thousand CAD | 212.05% |
| 2022 Q1 | -25.83 Thousand CAD | -248.26% |
| 2022 Q2 | 188.65 Thousand CAD | 830.15% |
| 2021 Q1 | 18.15 Thousand CAD | -79.69% |
| 2021 FY | 199.25 Thousand CAD | 286.35% |
| 2021 Q2 | 190.92 Thousand CAD | 951.4% |
| 2021 Q4 | 17.42 Thousand CAD | -92.08% |
| 2021 Q3 | 219.96 Thousand CAD | 15.21% |
| 2020 Q3 | - CAD | -100.0% |
| 2020 Q4 | 89.42 Thousand CAD | 0.0% |
| 2020 Q2 | 527.00 CAD | 0.0% |
| 2020 Q1 | - CAD | -100.0% |
| 2020 FY | 51.57 Thousand CAD | -62.01% |
| 2019 Q2 | 19.33 Thousand CAD | -57.19% |
| 2019 Q3 | - CAD | -100.0% |
| 2019 FY | 135.74 Thousand CAD | -89.38% |
| 2019 Q4 | 71.24 Thousand CAD | 0.0% |
| 2019 Q1 | 45.16 Thousand CAD | -64.38% |
| 2018 FY | 1.27 Million CAD | 23285.06% |
| 2018 Q4 | 126.77 Thousand CAD | -78.38% |
| 2018 Q1 | 545.57 Thousand CAD | 26487.62% |
| 2018 Q2 | 3378.00 CAD | -99.38% |
| 2018 Q3 | 586.36 Thousand CAD | 17258.23% |
| 2017 FY | 5468.00 CAD | -98.24% |
| 2017 Q3 | 2274.00 CAD | 355.71% |
| 2017 Q2 | 499.00 CAD | -22.4% |
| 2017 Q1 | 643.00 CAD | 100.72% |
| 2017 Q4 | 2052.00 CAD | -9.76% |
| 2016 Q2 | 393.6 Thousand CAD | 3999.74% |
| 2016 Q4 | -89.1 Thousand CAD | -3281.22% |
| 2016 Q3 | 2801.00 CAD | -99.29% |
| 2016 FY | 309.88 Thousand CAD | 251.22% |
| 2016 Q1 | -10.09 Thousand CAD | 86.69% |
| 2015 FY | -204.91 Thousand CAD | -236.14% |
| 2015 Q1 | -17.52 Thousand CAD | 71.35% |
| 2015 Q4 | -75.81 Thousand CAD | 0.0% |
| 2015 Q3 | - CAD | 100.0% |
| 2015 Q2 | -21.16 Thousand CAD | -20.77% |
| 2014 FY | 150.51 Thousand CAD | 417.44% |
| 2014 Q4 | -61.18 Thousand CAD | -223.06% |
| 2014 Q3 | -18.93 Thousand CAD | -109.24% |
| 2014 Q2 | 205.07 Thousand CAD | 269.01% |
| 2014 Q1 | 55.57 Thousand CAD | 393.18% |
| 2013 Q4 | -18.95 Thousand CAD | -284.04% |
| 2013 FY | -47.41 Thousand CAD | 0.0% |
| 2013 Q2 | -11.72 Thousand CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q3 | -4936.00 CAD | 57.89% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2006 FY | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.192% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 1027.369% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.294% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.246% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.024% |
| Mesoblast Limited | -35.16 Million USD | 99.918% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 15.763% |
| Genus plc | 178.7 Million USD | 100.016% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 107.014% |
| Marizyme, Inc. | 457.7 Thousand USD | 106.285% |
| ContraFect Corporation | -154 Thousand USD | 81.32% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -161.518% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 42.466% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 137.476% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 143.767% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 92.576% |
| MultiCell Technologies, Inc. | 49.32 USD | 58427.251% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.071% |
| EV Biologics, Inc. | 48.9 Thousand USD | 158.828% |
| Q BioMed Inc. | -8988.00 USD | -220.06% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.102% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -86.508% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.013% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 141.096% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 76.848% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 146.23% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -480.917% |
| Arch Therapeutics, Inc. | -2439.00 USD | -1079.459% |
| IMV Inc. | -962.29 Thousand USD | 97.011% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 120.475% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 70.5% |
| GB Sciences, Inc. | -624.00 USD | -4510.096% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 66.561% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Halberd Corporation | -208.00 USD | -13730.288% |
| Enzolytics Inc. | 30.7 Thousand USD | 193.679% |
| Resverlogix Corp. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 102.12% |
| SYBLEU INC | 11.69 Thousand USD | 345.956% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 105.963% |
| argenx SE | 1.1 Billion USD | 100.003% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.888% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 104.659% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.007% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -224.831% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.065% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 97.48% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 102.912% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.299% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 65.692% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.186% |
| ONE Bio Corp. | 20.12 Million USD | 100.143% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -143.067% |
| Cell Source, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 40.39% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 116.293% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 116.293% |
| NovAccess Global Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 94.409% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 95.435% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 0.803% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 106.392% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 90.996% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 100.624% |
| Bioxytran, Inc. | -8285.00 USD | -247.218% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 92.288% |
| Neutra Corp. | 14.33 Thousand USD | 300.677% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 64.918% |
| PureTech Health plc | -1.6 Million USD | 98.205% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 97.127% |
| IXICO plc | 3.27 Million USD | 100.88% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 95.855% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 98.394% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | 259.817% |